Extracellular MiRNAs As Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Feb 4

PMID 33535558

Citations 6

Authors

Mayu Ukai

Akira Yokoi

Kosuke Yoshida

Shiro Suzuki

Kiyosumi Shibata

Fumitaka Kikkawa

Tetsuya Nakatsura

Hiroaki Kajiyama

Affiliations

Soon will be listed here.

Abstract

Ovarian clear cell carcinoma (OCCC) has been treated with surgery and chemotherapy; however, the prognosis remains poor because of chemoresistance. Therefore, immunotherapies are attracting attention, including the GPC3 peptide vaccine, which improves overall survival. However, the response rate is limited and there are no sufficient predictive biomarkers that can identify responders before treatment. Our purpose was to identify circulating serum miRNAs as predictive biomarkers for response to GPC3 peptide vaccine. Eighty-four patients in a phase II trial of a GPC3 peptide vaccine were enrolled and miRNA sequencing was performed on their serum samples. Candidate miRNAs were selected from a group of 14 patients for whom treatment was responsive and validated in an independent group of 10 patients for whom treatment was responsive. Three markedly upregulated miRNAs, miR-375-3p, miR-193a-5p, and miR-1228-5p, were identified, and the combination of those miRNAs demonstrated high value in the prediction of the response. The origin of these miRNAs was assessed by referring to OCCC tissue miRNA profiles, and they were not identified as cancer tissue-related miRNAs. Functional annotation analysis suggested that they were associated with interferon-related pathways. The miRNAs identified herein have great potential to allow the realization of liquid biopsy for predicting the immunotherapy response and precision medicine.

Citing Articles

Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study.

Liu T, Gao Y, Li S, Xu S J Ovarian Res. 2024; 17(1):119.

PMID: 38824600 PMC: 11143660. DOI: 10.1186/s13048-024-01435-y.

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.

Pawlowska A, Rekowska A, Kurylo W, Panczyszyn A, Kotarski J, Wertel I Int J Mol Sci. 2023; 24(13).

PMID: 37446039 PMC: 10341806. DOI: 10.3390/ijms241310859.

Peptides for diagnosis and treatment of ovarian cancer.

Guo L, Wang J, Li N, Cui J, Su Y Front Oncol. 2023; 13:1135523.

PMID: 37213272 PMC: 10196167. DOI: 10.3389/fonc.2023.1135523.

Immunotherapeutic Approaches in Ovarian Cancer.

Yoon H, Kim A, Jang H Curr Issues Mol Biol. 2023; 45(2):1233-1249.

PMID: 36826026 PMC: 9955550. DOI: 10.3390/cimb45020081.

MicroRNAs: immune modulators in cancer immunotherapy.

Xing Y, Wang Z, Lu Z, Xia J, Xie Z, Jiao M Immunother Adv. 2022; 1(1):ltab006.

PMID: 35919742 PMC: 9327120. DOI: 10.1093/immadv/ltab006.

References

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

Hwang W, Adams S, Tahirovic E, Hagemann I, Coukos G . Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2011; 124(2):192-8. PMC: 3298445. DOI: 10.1016/j.ygyno.2011.09.039. View

Romano G, Kwong L . Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Rev. 2017; 37(1):45-53. DOI: 10.1007/s10555-017-9716-7. View

Rustin G, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T . Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21(2):419-23. DOI: 10.1097/IGC.0b013e3182070f17. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Garofalo M, Croce C . MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 2013; 16(3-5):47-59. PMC: 3858390. DOI: 10.1016/j.drup.2013.05.001. View

Ward A, Balwierz A, Zhang J, Kublbeck M, Pawitan Y, Hielscher T . Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2012; 32(9):1173-82. DOI: 10.1038/onc.2012.128. View

Goff B . Advanced ovarian cancer: what should be the standard of care?. J Gynecol Oncol. 2013; 24(1):83-91. PMC: 3549512. DOI: 10.3802/jgo.2013.24.1.83. View

Lim H, Ledger W . Targeted therapy in ovarian cancer. Womens Health (Lond). 2016; 12(3):363-78. PMC: 5384518. DOI: 10.2217/whe.16.4. View

10.

Kao S, Cheng Y, Williams M, Kirschner M, Madore J, Lum T . Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017; 12(9):1421-1433. DOI: 10.1016/j.jtho.2017.05.024. View

11.

Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P . miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016; 15(1):70. PMC: 5105253. DOI: 10.1186/s12943-016-0556-9. View

12.

Matsuyama H, Suzuki H, Nishimori H, Noguchi M, Yao T, Komatsu N . miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011; 118(26):6881-92. DOI: 10.1182/blood-2011-05-354654. View

13.

Fujiwara K, Shintani D, Nishikawa T . Clear-cell carcinoma of the ovary. Ann Oncol. 2016; 27 Suppl 1:i50-i52. DOI: 10.1093/annonc/mdw086. View

14.

Kijima T, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S . MicroRNA-6826 and -6875 in plasma are valuable non‑invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncol Rep. 2016; 37(1):23-30. PMC: 5355687. DOI: 10.3892/or.2016.5267. View

15.

Rodriguez-Galan A, Fernandez-Messina L, Sanchez-Madrid F . Control of Immunoregulatory Molecules by miRNAs in T Cell Activation. Front Immunol. 2018; 9:2148. PMC: 6167432. DOI: 10.3389/fimmu.2018.02148. View

16.

Graff J, Dickson A, Clay G, McCaffrey A, Wilson M . Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012; 287(26):21816-25. PMC: 3381144. DOI: 10.1074/jbc.M111.327031. View

17.

Fan Y, Liao J, Lu Y, Tian D, Ye F, Zhao P . MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma. Mol Ther Nucleic Acids. 2017; 7:181-189. PMC: 5415965. DOI: 10.1016/j.omtn.2017.03.010. View

18.

Odunsi K . Immunotherapy in ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii1-viii7. PMC: 5834124. DOI: 10.1093/annonc/mdx444. View

19.

Bagnoli M, Canevari S, Califano D, Losito S, Di Maio M, Raspagliesi F . Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 2016; 17(8):1137-1146. DOI: 10.1016/S1470-2045(16)30108-5. View

20.

Lindberg R, Hoffmann F, Mehling M, Kuhle J, Kappos L . Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol. 2010; 40(3):888-98. DOI: 10.1002/eji.200940032. View